rheumatoid arthritis and semaglutide ACR 2025: GLP-1 Drugs Reduce Flares I want to talk about

They're like, you either need to crack this and get an actual drug candidate in the pipeline within a year, or we're going to shut down this whole program

Providers typically reduce insulin or sulfonylurea doses when initiating semaglutide

Across multiple trials, tirzepatide demonstrated superior glycemic control compared to placebo, insulin, and other GLP-1 receptor agonists, with HbA1c reductions ranging from 1.9% to 2.6% depending on dose

Many patients using these medications have reported positive experiences, particularly regarding weight management

When your stores are low, all those things slow down and you feel low energy, weak, and just unwell